|
Market Closed -
Swiss Exchange
11:31:36 2026-10-21 EDT
|
5-day change | 1st Jan Change | ||
| 14.82 CHF | +0.82% |
|
+8.18% | +17.62% |
| 09-30 | Santhera Pharmaceuticals Holding AG, H1 2026 Earnings Call, Sep 30, 2026 | |
| 09-30 | Swiss Market Index Extends Losses Amid Higher Economic Growth Projections | MT |
Company Valuation: Santhera Pharmaceuticals Holding AG
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 55.82 | 75.32 | 90.32 | 167.3 | 168.5 | 226.8 | - | - |
| Change | - | 34.92% | 19.92% | 85.24% | 0.68% | 34.62% | - | - |
| Enterprise Value (EV) 1 | 55.82 | 75.32 | 90.32 | 167.3 | 168.5 | 247.1 | 240.2 | 243.5 |
| Change | - | 34.92% | 19.92% | 85.24% | 0.68% | 46.67% | -2.79% | 1.37% |
| P/E | -0.82x | -1.18x | 1.96x | - | - | - | - | - |
| PBR | 34.2x | -2.13x | - | - | - | - | - | - |
| PEG | - | 0x | -0x | - | - | - | - | - |
| Capitalization / Revenue | -35x | 10.1x | 0.87x | 4.28x | 2.18x | 2.39x | 1.96x | 1.77x |
| EV / Revenue | -35x | 10.1x | 0.87x | 4.28x | 2.18x | 2.61x | 2.08x | 1.9x |
| EV / EBITDA | -1.41x | -1.79x | 1.26x | - | - | -11.7x | 30.8x | 13.1x |
| EV / EBIT | -0.98x | -1.45x | 1.31x | - | -4.48x | -21.2x | 30.8x | 26.5x |
| EV / FCF | -1.49x | -2.53x | 3.84x | - | - | -88.2x | 11.1x | 11x |
| FCF Yield | -66.9% | -39.6% | 26% | - | - | -1.13% | 9.04% | 9.08% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -16.2 | -11.7 | 5.01 | - | - | - | - | - |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | -1.595 | 7.473 | 103.4 | 39.1 | 77.18 | 94.7 | 115.6 | 128.2 |
| EBITDA 1 | -39.57 | -42.12 | 71.89 | - | - | -21.1 | 7.8 | 18.6 |
| EBIT 1 | -56.89 | -51.98 | 68.81 | - | -37.61 | -11.66 | 7.804 | 9.2 |
| Net income | -55.53 | -70.15 | 54.78 | - | - | - | - | - |
| Net Debt 1 | - | - | - | - | - | 20.3 | 13.4 | 16.7 |
| Reference price 2 | 13.30 | 13.80 | 9.81 | 13.82 | 12.60 | 14.82 | 14.82 | 14.82 |
| Nbr of stocks (in thousands) | 4,197 | 5,458 | 9,207 | 12,106 | 13,369 | 15,302 | - | - |
| Announcement Date | 6/10/22 | 4/27/23 | 4/25/24 | 4/29/25 | 4/28/26 | - | - | - |
1CHF in Million2CHF
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | 2.59x | -11.62x | - | 273M | |
| 36.99x | 13.22x | 28x | 0.53% | 1,144B | |
| 37.96x | 6.39x | 17.99x | 2.06% | 625B | |
| 36.9x | 8.47x | 17.49x | 2.38% | 511B | |
| 21.13x | 5.1x | 12.68x | 2.57% | 377B | |
| 108.1x | 6.04x | 25.89x | 2.3% | 366B | |
| 21.5x | 5.61x | 13.79x | 2.85% | 291B | |
| 22.06x | 4.46x | 12.76x | 1.98% | 262B | |
| 27.87x | 7.15x | 12.8x | 2.3% | 237B | |
| -45.73x | 7.01x | 27.13x | 2.11% | 194B | |
| Average | 29.64x | 6.60x | 15.69x | 2.12% | 400.82B | |
| Weighted average by Cap. | 35.48x | 8.34x | 20.49x | 1.8% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- SANN Stock
- Valuation Santhera Pharmaceuticals Holding AG
Select your edition
All financial news and data tailored to specific country editions
